GDMC is an advanced therapeutic drug manufacturer that focuses on gene, tissue and cell biologics. The company emphasizes a “collaborative approach” and applies synthetic biology techniques to improve gene drug design and development. GDMC offers a “drug manufacturing organization partnership” model providing clients, including startups, with drug design, production, quality assurance, and regulatory support needed to reach market. It is developing advanced therapeutic modalities such as custom messenger RNA, plasmid DNA, and lentiviral vectors. GDMC recently closed a $21 million Series A financing. Investors in the round included Celadon Partners, Seeds Capital, NSG Ventures, and WI Harper Group.

Total raised

$21M

Funding rounds

1

Latest round

Series A

Latest activity

Jan 2024